Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.
What This Page Explains
Individuals with metabolic risk factors — including prediabetes, dyslipidemia, insulin resistance, and elevated cardiovascular risk — represent an investigational population for Urolithin A research. The most relevant human data comes from the Denk 2025 Nature Communications study, which included cardiovascular biomarker data alongside primarily preclinical findings. Other indirect evidence comes from metabolic biomarker endpoints in existing trials. Important: This page describes early-stage and investigational research. Urolithin A is not approved or recommended for the prevention or treatment of cardiovascular disease, diabetes, or any metabolic condition.
The $3.2 Billion Mistake the Supplement Industry Doesn't Want You to Know
They sell you antioxidants. You need mitochondrial support. There's a massive difference — and your energy levels prove it.
Detailed Evidence
SCIENTIFIC RATIONALE Mitochondrial dysfunction is increasingly recognized as a contributor to metabolic diseases including type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), and insulin resistance. Since Urolithin A activates mitophagy, researchers hypothesize it may improve metabolic function by restoring healthy mitochondrial pools in metabolically active tissues — skeletal muscle, liver, and cardiac muscle. DENK 2025 — NATURE COMMUNICATIONS STUDY This is the most relevant published study for metabolic risk populations. The study provided: (1) Preclinical evidence of cardioprotective effects — UA protected against ischemia-reperfusion injury in rodent hearts and improved mitochondrial quality in cardiac tissue, (2) A sub-analysis of human biomarker data suggesting improvements in certain cardiovascular health markers, (3) Mechanistic evidence that UA enhances mitochondrial quality in cardiomyocytes. However, the human component is a sub-analysis, not a prospective cardiovascular outcomes trial. INSULIN SENSITIVITY AND GLUCOSE METABOLISM In preclinical models, Urolithin A has improved glucose tolerance and insulin sensitivity in high-fat diet mice. However, published human trials have NOT reported significant changes in fasting glucose, HbA1c, or insulin sensitivity markers. The Singh 2022 trial showed improved acylcarnitines (mitochondrial fatty acid metabolism) but not standard metabolic panel markers. LIPID METABOLISM Preclinical data show improved lipid profiles in rodent models. In human trials, standard lipid panels (total cholesterol, LDL, HDL, triglycerides) have not shown significant changes with UA supplementation over 4 months. Whether longer supplementation periods or higher-risk populations would show lipid benefits is unknown. CARDIOVASCULAR BIOMARKERS Beyond the Denk 2025 data, the consistent reduction in C-reactive protein (CRP) across multiple UA trials is relevant to cardiovascular risk, as CRP is an established marker of systemic inflammation and cardiovascular risk. The ~30% CRP reduction seen in the Liu 2022 trial could be clinically relevant if sustained long-term — but this remains to be proven. WHY THIS REMAINS INVESTIGATIONAL The metabolic risk evidence is investigational because: (1) No trial has enrolled participants specifically selected for metabolic risk factors, (2) Standard metabolic endpoints (glucose, HbA1c, lipid panels) have not improved in published trials, (3) The cardiovascular evidence is primarily preclinical with one human sub-analysis, (4) CRP reduction — while potentially meaningful — is a surrogate marker, not a clinical outcome. Frequently Asked Questions: Can Urolithin A lower blood sugar? — No significant changes in fasting glucose or HbA1c in human trials. Does Urolithin A help with heart health? — Preclinical cardioprotection (Denk 2025) with limited human sub-analysis. Can Urolithin A lower cholesterol? — No significant lipid panel changes in human trials. Is Urolithin A safe for people with diabetes? — No specific safety data; trials enrolled healthy participants. Does Urolithin A reduce cardiovascular risk? — Unknown; no hard cardiovascular endpoints measured.
Evidence Hierarchy
Systematic Reviews & Meta-Analyses
Multiple high-quality trials combined
Randomized Controlled Trials (RCTs)
Gold standard for treatment efficacy
Observational Studies
Can show associations, not causation
Case Reports & Expert Opinion
Hypothesis-generating only
Preclinical (Lab/Animal) Studies
Should NOT be extrapolated to humans
Before You Spend Another Dollar on Supplements, Read This
Most supplements can't cross the mitochondrial membrane. ReCellence was designed specifically to reach where energy is made.
Study Quality Indicators
Higher Quality Indicators
- Large sample size (hundreds to thousands)
- Randomized and blinded design
- Placebo-controlled comparison
- Published in peer-reviewed journals
- Replicated in multiple studies
- Registered trial protocol before starting
Lower Quality Indicators
- Small sample size (under 100)
- No control group or blinding
- Manufacturer-funded with conflicts
- Only animal/cell studies
- Never replicated
- Published in predatory journals
Important Limitations
- • Supplement research often has methodological limitations
- • Results from one study may not generalize to all people
- • Marketing claims often exceed what research supports
- • Absence of evidence is not evidence of absence
- • Individual response to supplements varies widely
Quick Answers
Can Urolithin A help with metabolic risk factors?
The evidence is investigational. No trial enrolled participants selected for metabolic risk factors. Standard metabolic endpoints (glucose, HbA1c, lipids) did not improve. CRP decreased ~30%, which is relevant but a surrogate marker.
Does Urolithin A lower blood sugar?
No significant changes in fasting glucose or HbA1c have been reported in any published UA trial. Preclinical models show improved glucose tolerance, but this has not translated to human glycemic improvements.
Does Urolithin A improve heart health?
The Denk 2025 Nature Communications study provided preclinical cardioprotective evidence with a limited human biomarker sub-analysis. No prospective cardiovascular outcomes trial has been conducted.
Can Urolithin A lower cholesterol?
No. Standard lipid panels (total cholesterol, LDL, HDL, triglycerides) have not shown significant changes with UA supplementation over 4 months in human trials. Preclinical lipid improvements have not translated to humans.
What is the Denk 2025 cardiovascular study?
A Nature Communications study showing preclinical cardioprotective effects (protection against ischemia-reperfusion injury, improved cardiac mitochondrial quality) with a sub-analysis of human cardiovascular biomarkers showing improvement. The human component is a sub-analysis, not a prospective trial.
Does Urolithin A improve insulin sensitivity?
Preclinical models show improved insulin sensitivity in high-fat diet mice. No human trial has measured insulin sensitivity as an endpoint. This remains investigational.
Is Urolithin A safe for people with diabetes?
No specific safety data exists for people with diabetes — trials enrolled generally healthy participants. Individuals with diabetes should consult their healthcare provider before any supplementation.
Does Urolithin A reduce CRP (C-reactive protein)?
Yes. CRP decreased ~30% vs placebo over 4 months in the Liu 2022 trial. CRP is an established cardiovascular risk marker, but whether this reduction translates to reduced cardiovascular events is unknown.
Can Urolithin A prevent cardiovascular disease?
No. No trial has measured cardiovascular disease prevention. The Denk 2025 evidence is primarily preclinical with limited human sub-analysis. Prospective cardiovascular outcomes trials are needed.
What metabolic biomarkers changed in UA trials?
Plasma acylcarnitines (mitochondrial fatty acid metabolism markers) improved dose-dependently. Standard metabolic markers (glucose, HbA1c, lipid panels) did not change significantly. CRP decreased ~30%.
Why is metabolic evidence for UA considered investigational?
No trial enrolled metabolically at-risk participants, standard metabolic endpoints did not improve, cardiovascular evidence is primarily preclinical with one human sub-analysis, and CRP reduction is a surrogate marker — not a clinical outcome.
Does Urolithin A affect blood pressure?
No blood pressure data has been specifically reported as a primary or secondary endpoint in published UA trials. Blood pressure effects are unknown.
Could Urolithin A help with fatty liver disease?
Preclinical NAFLD models show reduced hepatic lipid accumulation. No human NAFLD studies have been conducted. This is investigational and UA is not a treatment for fatty liver disease.
Is Urolithin A better than statins for cholesterol?
No comparison has been made. Statins have robust evidence for cholesterol reduction and cardiovascular outcomes. UA has no significant lipid panel changes in human trials. They are not comparable.
What cardiovascular markers improved in the Denk 2025 study?
The human sub-analysis suggested improvements in certain cardiovascular health biomarkers. Specific markers were not fully detailed in the publicly available summary. The preclinical component showed improved cardiac mitochondrial quality and protection against ischemia-reperfusion injury.
Key Research Facts
No published human trial has been designed with metabolic or cardiovascular outcomes as primary endpoints for Urolithin A.
Strong EvidenceJayatunga et al., Ageing Research Reviews, 2024 — pubmed:39002645
The Denk 2025 Nature Communications study provided primarily preclinical evidence of cardioprotective effects, with limited human biomarker sub-analysis.
Moderate EvidenceDenk et al., Nature Communications — doi:10.1038/s41467-025-57067-3
C-reactive protein decreased ~30% in the UA group vs placebo in the Liu 2022 trial — CRP is an established cardiovascular risk marker.
Moderate EvidenceLiu et al., JAMA Network Open — doi:10.1001/jamanetworkopen.2021.44279
Standard metabolic markers (fasting glucose, HbA1c, lipid panels) did not show significant changes in published human UA trials over 4 months.
Strong EvidenceSingh et al., Cell Reports Medicine — doi:10.1016/j.xcrm.2022.100633
In preclinical models, Urolithin A improved glucose tolerance and insulin sensitivity in high-fat diet mice.
Moderate EvidenceD'Amico et al., Trends in Molecular Medicine — doi:10.1016/j.molmed.2021.04.009
Urolithin A protected against ischemia-reperfusion injury in rodent hearts and improved mitochondrial quality in cardiac tissue in the Denk 2025 study.
Moderate EvidenceDenk et al., Nature Communications — doi:10.1038/s41467-025-57067-3
Published human UA trials enrolled generally healthy participants — not those with diabetes, dyslipidemia, or cardiovascular disease.
Strong EvidenceClinical trial enrollment criteria — Andreux et al., 2019; Liu et al., 2022; Singh et al., 2022
Mitochondrial dysfunction is increasingly recognized as a contributor to type 2 diabetes, cardiovascular disease, and NAFLD.
Strong EvidenceD'Amico et al., Trends in Molecular Medicine — doi:10.1016/j.molmed.2021.04.009
Plasma acylcarnitines — mitochondrial fatty acid metabolism markers — improved dose-dependently in the Singh 2022 trial but are not standard metabolic endpoints.
Moderate EvidenceSingh et al., Cell Reports Medicine — doi:10.1016/j.xcrm.2022.100633
Prospective trials enrolling metabolically at-risk populations with hard cardiovascular endpoints are needed before any clinical recommendations can be made.
Strong EvidenceEvidence-based medicine standards — General clinical trial methodology
Citations & External Resources
ClinicalTrials.gov — Search: Urolithin A
FDA GRAS Notice GRN 000833 — Urolithin A
EFSA Novel Food Catalogue — Urolithin A
PubMed — Urolithin A research
Nature Medicine — Ryu et al. 2016 (Landmark Study)
JAMA Network Open — Liu et al. 2022 (Muscle Endurance RCT)
Nature Communications — Denk et al. 2025 (Cardiovascular Evidence)
AHA — American Heart Association Research
NIH NHLBI — Cardiovascular Risk Factors
Dear Reader: Your Body Is Begging For This
Every symptom — the fatigue, the brain fog, the slow recovery — is your mitochondria sending an SOS. Are you listening?
Related Reading
Urolithin A & Metabolic Health: Investigational Evidence
Urolithin A & Obesity: Investigational Research
Urolithin A & Inflammatory Biomarkers: What Studies Report
References (3)
Written by
ReCellence™ Editorial Team
Health Content Specialists
Medically reviewed by
Medical Review Board
MD, PhD
Last updated: March 8, 2026
Last medical review: March 8, 2026